123MO BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer
2021 ◽
Vol 32
◽
pp. S411-S412
P. Schmid
◽
F.J. Salvador Bofill
◽
B. Bermejo
◽
M. Phillips
◽
D. Wheatley
◽
...
H.L. McArthur
◽
E.A. Comen
◽
Y. Bryce
◽
S.B. Solomon
◽
J.H.S. Leal
◽
...
2013 ◽
Vol 22
(5)
◽
pp. 650-656
◽
Giuseppe Curigliano
◽
Xavier Pivot
◽
Javer Cortés
◽
Anthony Elias
◽
Rossano Cesari
◽
...
2021 ◽
pp. clincanres.3955.2020
Sherko Kuemmel
◽
Mario Campone
◽
Delphine Loirat
◽
Rafael López López
◽
J. Thaddeus Beck
◽
...
Y Fan
◽
BH Xu
◽
P Yuan
◽
JY Wang
◽
F Ma
◽
...
G Curigliano
◽
X Pivot
◽
J Cortes
◽
A Elias
◽
R Cesari
◽
...
2020 ◽
Vol 31
◽
pp. S305-S306
H. Bando
◽
N. Masuda
◽
T. Yamanaka
◽
T. Kadoya
◽
M. Takahashi
◽
...
J. O'Shaughnessy
◽
J. O'Shaughnessy
◽
J. O'Shaughnessy
◽
C. Osborne
◽
C. Osborne
◽
...
2014 ◽
Vol 32
(15_suppl)
◽
pp. TPS1145-TPS1145
Erica L. Mayer
◽
Ines Vaz-Luis
◽
Andrea L. Richardson
◽
Charles M. Perou
◽
Nadine M. Tung
◽
...
2021 ◽
pp. clincanres.2272.2021
Antoinette R. Tan
◽
Gail S. Wright
◽
Anu R. Thummala
◽
Michael A. Danso
◽
Lazar Popovic
◽
...
HL McArthur
◽
EA Comen
◽
S Solomon
◽
M Rodine
◽
C DiLauro Abaya
◽
...
Close
Export Citation Format
Close
Share Document
Close